Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of single- and
multiple-ascending oral doses of BIIB095 in healthy participants. The secondary objectives
are to characterize the single- and multiple-oral-dose PK of BIIB095 in healthy participants
and to investigate the effect of food on the single-oral-dose PK of BIIB095 in healthy
participants.